Why the study?
Do statins reduce perioperative mortality and cardiorenal complications in patients undergoing cardiac and major vascular procedures?
Do statins reduce perioperative mortality and cardiorenal complications in patients undergoing cardiac and major vascular procedures?
This review highlights the potential perioperative protective effects of statins beyond cholesterol lowering, emphasizing the need for future randomized trials.
May support perioperative statin consideration for cardiorenal protection; leaves open confirmation by high-quality RCTs.
Although statins decrease cholesterol synthesis, they also possess 'pleiotropic' effects, such as enhancing the function of vascular endothelium and the stability of atherosclerotic plaques. Furthermore, they attenuate oxidative stress, inflammation, and the prothrombotic response. These diverse biological actions may explain their perioperative protective effects, especially in patients undergoing cardiac and major vascular procedures. Beyond reductions in perioperative mortality and cardiorenal complications, recent evidence also suggests outcome benefits from statin exposure in sepsis, airway hyperreactivity, and venous thromboembolism. It is likely that these agents will be increasingly prescribed perioperatively as high-quality evidence from well-designed randomized trials becomes available in the near future.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: